Sunshine Biopharma Inc. (SBFM) - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on January 13, 2025, by Sunshine Biopharma Inc., a Colorado corporation with principal executive offices in Fort Lauderdale, FL. The report discloses the appointment of a new principal officer effective January 13, 2025.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial figures disclosed relate to executive compensation:
- Base Salary: $400,000 CAD annually for the new Chief Commercial Officer.
- Severance: $500,000 CAD payable in the event of termination without cause, plus statutory notice or compensation in lieu thereof.
Material Changes
The material change reported is the appointment of Mr. Michel Roy as Chief Commercial Officer. This represents a strategic addition to the executive team to lead commercial operations. No changes to capital structure, debt, or operational results are reported in this document.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of risks and contingencies beyond the standard employment terms. The appointment is intended to strengthen the company's commercial capabilities, leveraging Mr. Roy's extensive background in business development and sales within the pharmaceutical sector.
Key Facts for Investor Verification
- New Executive: Verify Mr. Michel Roy's background and prior roles at Shilpa Medicare Ltd. and Intas Pharmaceuticals Ltd.
- Compensation Terms: Note the salary is denominated in Canadian Dollars (CAD), which introduces currency exchange risk relative to the company's USD reporting.
- Severance Liability: Confirm the potential $500,000 CAD severance obligation in the event of termination without cause.
- Employment Duration: The employment agreement is for an indefinite term.